WallStreetZenWallStreetZen

NASDAQ: APYX
Apyx Medical Corp Stock

Open Broker Account
$1.97+0.06 (+3.14%)
Updated Dec 9, 2022
APYX Price
$1.97
Fair Value Price
$2.40
Market Cap
$68.16M
52 Week Low
$1.31
52 Week High
$13.78
P/E
-3.52x
P/B
1.62x
P/S
3.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$48.72M
Earnings
-$19.14M
Gross Margin
67.8%
Operating Margin
-38.53%
Profit Margin
-39.3%
Debt to Equity
0.31
Operating Cash Flow
-$16M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

APYX Overview

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Zen Score

Industry Average (32)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APYX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

APYX ($1.97) is undervalued by 17.93% relative to our estimate of its Fair Value price of $2.40 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
APYX ($1.97) is not significantly undervalued (17.93%) relative to our estimate of its Fair Value price of $2.40 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
APYX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APYX due diligence checks available for Premium users.

Be the first to know about important APYX news, forecast changes, insider trades & much more!

APYX News

Valuation

APYX fair value

Fair Value of APYX stock based on Discounted Cash Flow (DCF)
Price
$1.97
Fair Value
$2.40
Undervalued by
17.93%
APYX ($1.97) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APYX ($1.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APYX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

APYX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.52x
Industry
63.47x
Market
21.21x

APYX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.62x
Industry
3.8x
APYX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

APYX's financial health

Profit margin

Revenue
$9.1M
Net Income
-$5.8M
Profit Margin
-63.2%
APYX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
APYX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$55.3M
Liabilities
$13.1M
Debt to equity
0.31
APYX's short-term assets ($46.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APYX's short-term assets ($46.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APYX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APYX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.4M
Investing
-$188.0k
Financing
$127.0k
APYX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

APYX vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
APYX$68.16M+3.14%-3.52x1.62x
TMDI$73.81M-4.20%-3.67x10.61x
LUCD$73.91M-1.05%-1.29x2.68x
RPID$76.85M-1.61%11.44x0.43x
OWLT$76.95M-7.20%-1.00x17.41x

Apyx Medical Stock FAQ

What is Apyx Medical's quote symbol?

NASDAQ: APYX) Apyx Medical trades on the NASDAQ under the ticker symbol APYX. Apyx Medical stock quotes can also be displayed as NASDAQ: APYX.

If you're new to stock investing, here's how to buy Apyx Medical stock.

What is the 52 week high and low for Apyx Medical (NASDAQ: APYX)?

(NASDAQ: APYX) Apyx Medical's 52-week high was $13.78, and its 52-week low was $1.31. It is currently -85.7% from its 52-week high and 50.38% from its 52-week low.

How much is Apyx Medical stock worth today?

(NASDAQ: APYX) Apyx Medical currently has 34,597,822 outstanding shares. With Apyx Medical stock trading at $1.97 per share, the total value of Apyx Medical stock (market capitalization) is $68.16M.

Apyx Medical stock was originally listed at a price of $0.70 in Feb 22, 1999. If you had invested in Apyx Medical stock at $0.70, your return over the last 23 years would have been 181.43%, for an annualized return of 4.6% (not including any dividends or dividend reinvestments).

How much is Apyx Medical's stock price per share?

(NASDAQ: APYX) Apyx Medical stock price per share is $1.97 today (as of Dec 9, 2022).

What is Apyx Medical's Market Cap?

(NASDAQ: APYX) Apyx Medical's market cap is $68.16M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Apyx Medical's market cap is calculated by multiplying APYX's current stock price of $1.97 by APYX's total outstanding shares of 34,597,822.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.